Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This study assessed the initial efficacy and safety of canakinumab over a 4 week period in
patients with systemic juvenile idiopathic arthritis (SJIA) having a flare. Response to
treatment will be according to the adapted American College of Rheumatology(ACR)Pediatric 30
criteria at Day 15.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborators:
International Maternal Pediatric Adolescent AIDS Clinical Trials Group Southwest Pediatric Nephrology Study Group